Medtronic Evolut FX Delivery Catheter System; EvolutTranscatheter Aortic Valve System
Medtronic, Inc. · Decision date Aug 10, 2026
What did the FDA decide?
FDA records P130021/S187 as a supplement to PMA P130021, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 10, 2026.
FDA approval order statement
to introduce an alternative supplier for a component of the Evolut FX delivery catheter system
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 10, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P130021/S187
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- NPT
- Decision code
- OK30
- Decision date
- Aug 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Aortic valve, prosthesis, percutaneously delivered.
- Applicant
- Medtronic, Inc.
- Product code
- NPT
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P130021. Subsequent supplements may change the device or its indications.
FDA decision timeline
P130021 · Original PMA
MEDTRONIC COREVALVE SYSTEM
P130021/S177 · Related supplement
Medtronic CoreValve Evolut PRO Transcatheter Aortic Valve; Medtronic Evolut PRO+ Transcatheter Aortic Valve; Medtroni
P130021/S174 · Related supplement
Evolut PRO+ System, Evolut FX System, Evolut FX+ System
P130021/S178 · Related supplement
Medtronic Evolut PRO+ Delivery Catheter System
P130021/S180 · Related supplement
Medtronic CoreValve Evolut PRO Transcatheter Aortic Valve (EVOLUTPRO-23-US, EVOLUTPRO-26-US, EVOLUTPRO-29-US); Medtron
P130021/S183 · Related supplement
Medtronic CoreValve Evolut PRO Transcatheter Aortic Valve; Medtronic Evolut PRO+ Transcatheter Aortic Valve; Medtroni
P130021/S181 · Related supplement
EnVeo PRO Delivery Catheter System (ENVPRO-16-US), Evolut PRO+ Delivery Catheter System (D-EVPROP2329US, D-EVPROP34US),
P130021/S179 · Related supplement
Evolut PRO, PRO+, FX, FX+
P130021/S182 · Related supplement
CoreValve EnVeo Pro Delivery Catheter System; Evolut PRO+ Delivery Catheter System; Evolut FX Delivery Catheter System
P130021/S184 · Related supplement
Medtronic CoreValve EnVeo PRO Delivery Catheter System; Medtronic Evolut PRO+ Delivery Catheter System; Medtronic Evolut
P130021/S186 · Related supplement
Medtronic CoreValve Evolut PRO Transcatheter Aortic Valve
P130021/S185 · Related supplement
Medtronic Evolut PRO+ Transcatheter Aortic Valve Replacement System; Medtronic Evolut FX Transcatheter Aortic Valve Repl
P130021/S187 received
Application receipt date recorded by FDA.
P130021/S187 · FDA decision
30-Day Notice
P130021/S188 · Related supplement
Evolut FX Delivery Catheter System of the Evolut FX Transcatheter Aortic Valve System; Evolut FX+ Transcatheter Aorti
Timeline entries are records held by MedtechLedger for P130021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MEDTRONIC COREVALVE SYSTEMP130021 | Medtronic, Inc. | PMA approval | Jan 17, 2014 | FDA |
| Medtronic, Inc. | PMA supplement | Aug 14, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Aug 27, 2025 | FDA | |
Medtronic Evolut PRO+ Delivery Catheter SystemP130021/S178 | Medtronic, Inc. | PMA supplement | Oct 22, 2025 | FDA |
| Medtronic, Inc. | PMA supplement | Feb 4, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Feb 10, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Feb 11, 2026 | FDA | |
Evolut PRO, PRO+, FX, FX+P130021/S179 | Medtronic, Inc. | PMA supplement | Feb 12, 2026 | FDA |
| Medtronic, Inc. | PMA supplement | Feb 26, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Mar 27, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Jun 1, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Jul 14, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Nov 7, 2026 | FDA |
Explore the linked device profile
Other records with product code NPT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 29, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 22, 2026 | FDA | |
Trilogy Transcatheter Heart Valve SystemP250024/S005 | JenaValve Technology, Inc. | PMA supplement | Oct 13, 2026 | FDA |
Trilogy Transcatheter Heart Valve SystemP250024/S006 | JenaValve Technology, Inc. | PMA supplement | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 710 Medtronic Pkwy., Miinneapolis, MN, 55432
Sources and methodology
- Original FDA record: P130021/S187
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records